Secondary adrenal insufficiency secondary prevention
Secondary adrenal insufficiency Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Secondary adrenal insufficiency secondary prevention On the Web |
American Roentgen Ray Society Images of Secondary adrenal insufficiency secondary prevention |
Secondary adrenal insufficiency secondary prevention in the news |
Blogs on Secondary adrenal insufficiency secondary prevention |
Risk calculators and risk factors for Secondary adrenal insufficiency secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
Secondary Prevention
Effective measures for the secondary prevention of [disease name] include:
- Patient and family members involved in patient care should be properly educated about risks of hormone replacement therapy.[1][2]
- Patient should also be educated about dose adjustments during acute illnesses.[3][4]
- Asymptomatic patients can also wear an identification bracelet stating the name of the disease to ensure proper emergency treatment during an adrenal crisis.[5]
References
- ↑ Tucci V, Sokari T (2014). "The clinical manifestations, diagnosis, and treatment of adrenal emergencies". Emerg. Med. Clin. North Am. 32 (2): 465–84. doi:10.1016/j.emc.2014.01.006. PMID 24766944.
- ↑ Napier C, Pearce SH (2014). "Current and emerging therapies for Addison's disease". Curr Opin Endocrinol Diabetes Obes. 21 (3): 147–53. doi:10.1097/MED.0000000000000067. PMID 24755997.
- ↑ Napier C, Pearce SH (2012). "Autoimmune Addison's disease". Presse Med. 41 (12 P 2): e626–35. doi:10.1016/j.lpm.2012.09.010. PMID 23177474.
- ↑ Quinkler M (2012). "[Addison's disease]". Med Klin Intensivmed Notfmed (in German). 107 (6): 454–9. doi:10.1007/s00063-012-0112-3. PMID 22907517.
- ↑ Hahner S, Allolio B (2005). "Management of adrenal insufficiency in different clinical settings". Expert Opin Pharmacother. 6 (14): 2407–17. doi:10.1517/14656566.6.14.2407. PMID 16259572.